AstraZeneca announces results from interim analysis of ECHO Phase III trial

Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, PFS, versus standard of care in previously untreated adult patients with mantle cell lymphoma, MCL. A trend was observed in favour of Calquence plus chemoimmunotherapy for the secondary endpoint of overall survival, OS. The OS data were not mature at the time of this analysis and the trial will continue to assess OS. The safety and tolerability of Calquence was consistent with its known safety profile, and no new safety signals were identified. The data will be presented at a forthcoming medical meeting and shared with global regulatory authorities. As part of an extensive clinical development programme, AstraZeneca is currently evaluating Calquence alone and in combination for the treatment of multiple B-cell blood cancers, including chronic lymphocytic leukaemia, MCL, and diffuse large B-cell lymphoma.